Apollo Proton Cancer Centre introduces India’s first Robotic Surgery Program for ovarian cancer

Breakthrough surgeries mark a significant advancement in cancer treatment, offering new hope for patients battling advanced ovarian cancers

0
45
New Delhi: Apollo Proton Cancer Centre (APCC) has unveiled India’s pioneering Robotic Surgery Program for Ovarian Cancers. The centre completed India’s First Robotic Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for two patients with advanced ovarian cancers.
Compared to traditional open surgeries, robotic-assisted interval cytoreductive surgery significantly reduces hospital stay from 10 to 3 days and minimizes blood loss and post-operative pain. The robotic system allows clinicians to access multiple deep areas of the abdomen effectively, enhancing patient comfort, and enabling quicker recovery. Patients benefit from a faster return of bowel function and quicker resumption of normal activities, including timely continuation of adjuvant therapies.
Dr. Venkat P, Senior Consultant – Surgical Oncology, Apollo Proton Cancer Centre, said, “At Apollo Proton Cancer Centre, we are continually advancing our capabilities in robotic technology. The dual surgeries for advanced ovarian cancer utilized cutting-edge robotic systems that provide superior precision and flexibility. In these particular cases, the ability to achieve optimal cytoreduction while preserving healthy tissues is crucial for the patient’s long-term prognosis.”
Dr. Priya Kapoor, Consultant – Surgical Oncology, Apollo Proton Cancer Centre, highlighted, “The new approach– Robotic Cytoreductive Surgery with HIPEC– is a testament to our meticulous planning and the precision that robotic surgery offers. This approach significantly enhances the efficacy of the treatment while reducing the typical complications associated with open surgeries.”
One of the patients, 48-year-old Thara from Guwahati, suffering from carcinoma of the ovary, underwent a complex robotic-assisted interval cytoreductive surgery after receiving neoadjuvant chemotherapy. The procedure, performed with minimal morbidity, included extensive surgical clearance followed by HIPEC. Remarkably, Thara was also diagnosed with breast cancer during her workup and could undergo surgery for both cancers in the same sitting and was also discharged in three days, thanks to the precision of robotic technology.
Similarly, Amala, a 40-year-old patient from Chennai, battled against the recurrence of a rare tumor called extrauterine endometrial stromal sarcoma and underwent extensive robotic cytoreductive surgery, showcasing the versatility of robotic surgery in treating complex cancer recurrences.